REAL-WORLD CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH METASTATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL IRINOTECAN-BASED REGIMENS BY RACE

被引：0
|
作者：
Kim, G. P. [1 ]
Cockrum, P. [2 ]
Lamarre, N. [3 ]
Surinach, A. [3 ]
机构：
[1] George Washington Univ, Washington, DC USA
[2] Ipsen, Cambridge, MA USA
[3] Genesis Res, Hoboken, NJ USA
来源：
VALUE IN HEALTH | 2021年 / 24卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN27
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [21] Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States
    Barzi, Afsaneh
    Miksad, Rebecca
    Surinach, Andy
    Corvino, Frank A.
    Wang, Siqi
    Torres, Aracelis Z.
    Mamlouk, Khalid
    Pulgar, Sonia
    Valderrama, Adriana
    Bekaii-Saab, Tanios
    Ahn, Daniel
    PANCREAS, 2020, 49 (02) : 193 - 200
  • [22] Outcomes of Irinotecan-Based Chemotherapy Regimens in Elderly Medicare Patients With Metastatic Colorectal Cancer
    Obeidat, Nour A.
    Pradel, Francoise G.
    Zuckerman, Ilene H.
    DeLisle, Sylvain
    Mullins, C. Daniel
    AMERICAN JOURNAL OF GERIATRIC PHARMACOTHERAPY, 2009, 7 (06): : 343 - 354
  • [23] Real-world prognostic factors for survival among treated patients with metastatic pancreatic ductal adenocarcinoma
    Yu, Kenneth H.
    Ozer, Muhammet
    Cockrum, Paul
    Surinach, Andy
    Wang, Shu
    Chu, Bong Chul
    CANCER MEDICINE, 2021, 10 (24): : 8934 - 8943
  • [24] Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience
    Gupta, Amol
    Kamel, Ihab R.
    Laheru, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] REAL-WORLD 30-DAY READMISSION PATTERNS AMONG COMMERCIALLY INSURED PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
    Kim, G. P.
    Surinach, A.
    Cockrum, P.
    VALUE IN HEALTH, 2022, 25 (07) : S310 - S311
  • [26] Dosing patterns and treatment patterns in real-world patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) who received FOLFIRINOX in the first line
    MacEwan, Joanna P.
    Silver, Michelle
    Cockrum, Paul
    Sanders, Chad
    Kim, George P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Assessing real-world survival outcomes of patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first-line FOLFIRINOX compared to patients from a phase 1/2 trial treated with NALIRIFOX.
    Zhu, Xuelian
    Cockrum, Paul
    Shah, Bonny
    Parzynski, Craig
    Garawin, Tamer
    Maxwell, Fiona
    Surinach, Andy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
    Verbruggen, Lise
    Verheggen, Lisa
    Vanhoutte, Greetje
    Loly, Catherine
    Lybaert, Willem
    Borbath, Ivan
    Vergauwe, Philippe
    Hendrickx, Koen
    Debeuckelaere, Celine
    de Haar-Holleman, Amy
    Van Laethem, Jean-Luc
    Peeters, Marc
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [29] A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium
    Verbruggen, Lise
    Verheggen, Lisa
    Vanhoutte, Greetje
    Loly, Catherine
    Lybaert, Willem
    Borbath, Ivan
    Vergauwe, Philippe
    Hendrickx, Koen
    Debeuckelaere, Celine
    de Haar-Holleman, Amy
    Van Laethem, Jean-Luc
    Peeters, Marc
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [30] IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING
    Kim, G. P.
    Surinach, A.
    Corvino, F. A.
    Cockrum, P.
    VALUE IN HEALTH, 2019, 22 : S58 - S58
12345